Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Total Current Liabilities (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Total Current Liabilities readings, the most recent being $12.9 million for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 85.92% to $12.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.9 million, a 85.92% increase, with the full-year FY2025 number at $12.9 million, up 85.92% from a year prior.
  • Total Current Liabilities hit $12.9 million in Q4 2025 for Avalo Therapeutics, up from $8.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $215.7 million in Q1 2024 to a low of $4.6 million in Q4 2023.
  • Median Total Current Liabilities over the past 5 years was $18.6 million (2021), compared with a mean of $31.6 million.
  • Biggest five-year swings in Total Current Liabilities: soared 910.39% in 2024 and later tumbled 97.4% in 2025.
  • Avalo Therapeutics' Total Current Liabilities stood at $19.9 million in 2021, then grew by 11.19% to $22.1 million in 2022, then plummeted by 79.12% to $4.6 million in 2023, then skyrocketed by 50.71% to $7.0 million in 2024, then surged by 85.92% to $12.9 million in 2025.
  • The last three reported values for Total Current Liabilities were $12.9 million (Q4 2025), $8.0 million (Q3 2025), and $9.3 million (Q2 2025) per Business Quant data.